secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027445
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q2 revenue $13.2M, down 55% YoY; adjusted EBITDA loss $2.2M
-------------------------------------------------------------------------

- Revenue $13.2M vs $29.1M YoY; diagnostic services fell $18.3M as COVID testing slowed.
- Gross margin fell to 48.8% from 64.3%; net working capital $40.2M.
- Nebula Genomics whole genome sequencing facility could generate ~$40M annual revenue at capacity.
- Pharmaloz Manufacturing revenue up >50% YoY; additional lozenge line planned for early 2024.
- Equivir trial enrollment commenced in India; BE-SMART test progressed with over 200 specimens.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315223027445/0001493152-23-027445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315223027445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer